Contineum Therapeutics (CTNM) Operating Leases (2023 - 2026)

Contineum Therapeutics' Operating Leases history runs 4 years deep, the most recent figure standing at $6.6 million for Q2 2026.

• In Q2 2026, Operating Leases rose 53.45% year-over-year to $6.6 million; the TTM figure through Jun 2026 stood at $6.6 million (up 53.45% YoY), while the FY2025 annual figure was $8.2 million, up 31.81% from the prior year.
• Operating Leases for Q2 2026 stood at $6.6 million, down from $7.0 million in the prior quarter.
• The five-year high for Operating Leases was $8.2 million in Q4 2025, with the low at $108000.0 in Q4 2023.
• The 4-year median for Operating Leases is $4.4 million (2025), against an average of $4.1 million.
• The sharpest annual moves came in 2024 and 2025: Operating Leases surged 5695.37% in 2024, then soared 31.81% in 2025.
• Contineum Therapeutics' Operating Leases stood at $108000.0 in 2023, then soared by 5695.37% to $6.3 million in 2024, then surged by 31.81% to $8.2 million in 2025, then retreated by 20.32% to $6.6 million in 2026.
• Business Quant data shows CTNM's Operating Leases at $6.6 million in Q2 2026, $7.0 million in Q1 2026, and $8.2 million in Q4 2025.